ClinicalTrials.gg

Program

durvalumab

Also written as “Durvalumab”, “MEDI4736” and “MEDI4736 (Durvalumab)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Carcinoma, Hepatocellular · Urinary Bladder Neoplasms · Squamous Cell Carcinoma of Head and Neck, led by 8 companies.

Furthest: phase 4, since May 27, 2020100 company-led studies, 45 open or runningNext primary completion: Nov 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca8643 open or runningphase 4since May 27, 2020Sep 14, 2012Nov 30, 2026phase 2 · NCT07081633
Bristol-Myers Squibb70 open or runningphase 2since Feb 16, 2016Nov 25, 2015none ahead
AbbVie20 open or runningphase 2since Feb 27, 2015Feb 27, 2015none ahead
Academic Thoracic Oncology Medical Investigators Consortium10 open or runningphase 2since Jul 22, 2016Jul 22, 2016none ahead
Advaxis10 open or runningphase 2since Nov 6, 2014Nov 6, 2014none ahead
AGO Research11 open or runningphase 2since Nov 11, 2020Nov 11, 2020Jan 2028phase 2 · NCT04644289
Boston Scientific11 open or runningphase 2since Sep 1, 2021Sep 1, 2021Jun 2027phase 2 · NCT05063565
Eli Lilly10 open or runningphase 1since Oct 7, 2015Oct 7, 2015none ahead

Also a collaborator on its studies: jazz-pharmaceuticals-ireland-limited, biocompatibles-uk-ltd, Daiichi Sankyo, parexel, apices-soluciones-s-l, iqvia-pty-ltd, myriad-genetic-laboratories-inc, pra-health-sciences and Johnson & Johnson.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Dec 15, 2016.

  1. May 22, 2023Phase 3 study in Liver NeoplasmsAstraZeneca · NCT05883644 · 111 enrolled · United States, France, Germany and more
  2. Jun 1, 2023Phase 3 study in Biliary Tract NeoplasmsAstraZeneca · NCT05924880 · 116 enrolled · China
  3. Jun 22, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05925530 · 142 enrolled · United States, Austria, Canada and more
  4. Jul 5, 2023Phase 3 study in Non-Muscle Invasive Bladder NeoplasmsAstraZeneca · NCT05943106 · 100 enrolled · United States
  5. Aug 17, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06008093 · 103 enrolled · United States
  6. Sep 11, 2023Phase 2 study in Carcinoma, HepatocellularAstraZeneca · NCT06040099 · 58 enrolled · United States
  7. Oct 23, 2023Phase 3 study in Breast NeoplasmsAstraZeneca · NCT06103864 · 625 planned · United States, Argentina, Australia and more
  8. Nov 28, 2024Phase 3 study in Endometrial NeoplasmsAstraZeneca · NCT06746116 · 45 enrolled · Spain
  9. Apr 29, 2025Phase 2 study in Urinary Bladder NeoplasmsAstraZeneca · NCT06960577 · 150 planned · Australia, Brazil, Canada and more
  10. May 12, 2025Phase 3 study in Small Cell Lung CarcinomaAstraZeneca · NCT06992609 · 71 enrolled · Spain
  11. Jun 23, 2025Phase 2 study in Carcinoma, HepatocellularAstraZeneca · NCT07081633 · 114 enrolled · China, Hong Kong
  12. Jan 30, 2026Phase 1 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT07391670 · 40 planned · Australia, Georgia, Poland and more
  13. Sep 15, 2026Phase 3 study in GastricAstraZeneca · NCT07877818 · 140 planned · China
  14. Oct 9, 2026Phase 4 study in Muscle-Invasive Bladder Cancer (MIBC)AstraZeneca · NCT07876817 · 50 planned

Ahead

  1. Nov 30, 2026Primary completion: phase 2 study in Carcinoma, HepatocellularAstraZeneca · NCT07081633
  2. Jun 2027Primary completion: phase 2 study in Carcinoma, HepatocellularBoston Scientific · NCT05063565
  3. Jun 30, 2027Primary completion: phase 3 study in Esophageal Squamous Cell CarcinomaAstraZeneca · NCT04550260
  4. Jul 28, 2027Primary completion: phase 3 study in Breast NeoplasmsAstraZeneca · NCT06103864

TargetBeta

CD274 →read by rule
“A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) ”NCIt, by rule
“Programmed cell death 1 ligand 1 inhibitor”ChEMBL 37, by rule

Other programs on CD274

ProgramCompanyFurthest phaseStudies
adebrelimabruleJiangsu HengRui Medicinephase 351
pumitamigBioNTechphase 334
benmelstobartruleSino Biopharmaceuticalphase 333
retlirafusp alfaruleJiangsu HengRui Medicinephase 320
Anti-PD-L1 Antibody-drug Conjugate HLX43Fosun Pharmaphase 317
erfonrilimabruleAlphamab Oncologyphase 314
Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rulenanjing-leads-biolabs-co-ltdphase 310
socazolimabruleLee's Pharmaceuticalphase 39
acasunlimabruleGenmabphase 36
sotiburafusp alfarulehuabo-biopharm-co-ltdphase 35
fetrastobart vedotinPfizerphase 32
HLX37Fosun Pharmaphase 32

Studies

The newest 60 of 100 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07876817Muscle-Invasive Bladder Cancer (MIBC)4Not yet recruitingAstraZenecaJan 31, 202950
NCT07877818Gastric · China3RecruitingAstraZenecaNov 1, 2029140
NCT07391670Carcinoma, Non-Small-Cell Lung · Australia, Georgia, Poland and more1RecruitingAstraZenecaAug 30, 202740
NCT07081633Carcinoma, Hepatocellular · China, Hong Kong2Active, not recruitingAstraZenecaNov 30, 2026114
NCT06992609Small Cell Lung Carcinoma · Spain3Active, not recruitingAstraZenecaJun 30, 202971
NCT06960577Urinary Bladder Neoplasms · Australia, Brazil, Canada and more2RecruitingAstraZenecaAug 30, 2028150
NCT06746116Endometrial Neoplasms · Spain3Active, not recruitingAstraZenecaNov 30, 202845
NCT06103864Breast Neoplasms · United States, Argentina, Australia and more3RecruitingAstraZenecaJul 28, 2027625
NCT06040099Carcinoma, Hepatocellular · United States2Active, not recruitingAstraZenecaJun 30, 202658
NCT06008093Carcinoma, Non-Small-Cell Lung · United States2Active, not recruitingAstraZenecaOct 27, 2026103
NCT05943106Non-Muscle Invasive Bladder Neoplasms · United States3Active, not recruitingAstraZenecaJun 16, 2025100
NCT05925530Carcinoma, Non-Small-Cell Lung · United States, Austria, Canada and more2Active, not recruitingAstraZenecaJan 12, 2026142
NCT05924880Biliary Tract Neoplasms · China3CompletedAstraZenecaFeb 7, 2025116
NCT05883644Liver Neoplasms · United States, France, Germany and more3Active, not recruitingAstraZenecaMar 30, 2026111
NCT05771480Biliary Tract Neoplasms · United States, France, Germany and more3Active, not recruitingAstraZenecaOct 2, 2025142
NCT05629585Breast Neoplasms · United States, Belgium, Brazil and more3Active, not recruitingAstraZenecaSep 1, 20271,174
NCT05557838Carcinoma, Hepatocellular · China3Active, not recruitingAstraZenecaSep 30, 2026214
NCT05498155Breast Neoplasms · United States, Australia, Austria and more2CompletedAstraZenecaNov 20, 202450
NCT05063565Carcinoma, Hepatocellular · United States, France, Italy and more2Active, not recruitingBoston ScientificJun 2027100
NCT05043090Carcinoma, Renal Cell · United States, Argentina, Australia and more3Active, not recruitingAstraZenecaDec 31, 2025148
NCT04960709Urinary Bladder Neoplasms · United States, Argentina, Austria and more3Active, not recruitingAstraZenecaMar 2, 2026712
NCT04870112Carcinoma, Non-Small-Cell Lung · United States, New Zealand, Spain and more1TerminatedAstraZenecaAug 30, 202318
NCT04774380Small Cell Lung Carcinoma · Bulgaria, Canada, Czechia and more3CompletedAstraZenecaJun 12, 2023152
NCT04712903Small Cell Lung Carcinoma Extensive Disease · Spain3CompletedAstraZenecaJun 21, 2023101
NCT04644289Carcinoma, Ovarian Epithelial · Germany2RecruitingAGO ResearchJan 202860
NCT04642469Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3CompletedAstraZenecaMay 31, 202330
NCT04550260Esophageal Squamous Cell Carcinoma · United States, Belgium, Brazil and more3Active, not recruitingAstraZenecaJun 30, 2027640
NCT04592913Gastrointestinal Neoplasms · United States, Argentina, Belgium and more3Active, not recruitingAstraZenecaDec 20, 2024957
NCT04416633Unresectable Non-small Cell Lung Cancer (NSCLC) · India4CompletedAstraZenecaOct 27, 2023100
NCT04449861Small Cell Lung Carcinoma Extensive Disease · China3CompletedAstraZenecaMar 30, 2023166
NCT04385368Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3CompletedAstraZenecaAug 31, 202389
NCT04269200Endometrial Neoplasms · United States, Australia, Belgium and more3Active, not recruitingAstraZenecaJul 8, 2024805
NCT04249362Carcinoma, Non-Small-Cell Lung · United States, France, Italy and more2CompletedAstraZenecaMar 30, 2023102
NCT04145193Colonic Neoplasms2WithdrawnAstraZenecaMar 19, 20240
NCT03944772Carcinoma, Non-Small-Cell Lung · United States, Denmark, Italy and more2Active, not recruitingAstraZenecaMay 6, 2025247
NCT03875235Biliary Tract Neoplasms · United States, Argentina, Bulgaria and more3Active, not recruitingAstraZenecaAug 11, 2021810
NCT03847428Carcinoma, Hepatocellular · United States, Australia, Austria and more3CompletedAstraZenecaMay 15, 2026908
NCT03833154Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more3Active, not recruitingAstraZenecaOct 31, 2028724
NCT03819465Carcinoma, Non-Small-Cell Lung · United States, Austria, Belgium and more1Active, not recruitingAstraZenecaMay 23, 2023175
NCT03822351Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more2CompletedAstraZenecaJul 18, 2023189
NCT03794544Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more2CompletedAstraZenecaJan 13, 202184
NCT03800134Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more3Active, not recruitingAstraZenecaNov 10, 2022825
NCT03830866Locally Advanced Cervical Cancer · United States, Brazil, Chile and more3CompletedAstraZenecaJan 20, 2022770
NCT03778957Carcinoma, Hepatocellular · United States, Australia, Brazil and more3Active, not recruitingAstraZenecaSep 11, 2023724
NCT03737643Ovarian Neoplasms · United States, Austria, Belgium and more3Active, not recruitingAstraZenecaMar 17, 20251,407
NCT03732677Urinary Bladder Neoplasms · United States, Australia, Belgium and more3Active, not recruitingAstraZenecaApr 29, 20241,063
NCT03703297Small Cell Lung Carcinoma · United States, Argentina, Belgium and more3Active, not recruitingAstraZenecaJan 15, 2024730
NCT03693300Carcinoma, Non-Small-Cell Lung · United States, France, Germany and more2CompletedAstraZenecaDec 13, 2022117
NCT03682068Urinary Bladder Neoplasms · United States, Argentina, Australia and more3Active, not recruitingAstraZenecaJun 1, 20261,246
NCT03706690Carcinoma, Non-Small-Cell Lung · China, Hong Kong, India and more3Active, not recruitingAstraZenecaJun 23, 2024407
NCT03519971Carcinoma, Non-Small-Cell Lung · Brazil, Czechia, Hungary and more3CompletedAstraZenecaSep 7, 2023328
NCT03509012Squamous Cell Carcinoma of Head and Neck · United States, Japan, Korea, Republic of and more1CompletedAstraZenecaDec 31, 2020105
NCT03528694Non-Muscle Invasive Bladder Neoplasms · Australia, Austria, Belgium and more3Active, not recruitingAstraZenecaApr 3, 20251,018
NCT03298451Carcinoma, Hepatocellular · United States, Brazil, Canada and more3Active, not recruitingAstraZenecaAug 27, 20211,324
NCT03164616Non Small Cell Lung Cancer NSCLC · United States, Brazil, Bulgaria and more3Active, not recruitingAstraZenecaMar 12, 20211,186
NCT03084471Diabetes Mellitus, Insulin-Dependent, 12 · United States, Canada, France and more3CompletedAstraZenecaMar 31, 2020867
NCT03043872Small Cell Lung Carcinoma · United States, Argentina, Austria and more3Active, not recruitingAstraZenecaJan 27, 2020987
NCT03003520Lymphoma, Large B-Cell, Diffuse · United States, Austria, Denmark and more2CompletedBristol-Myers SquibbApr 24, 202246
NCT03000452Multiple Myeloma · United States, Austria, Greece and more2CompletedBristol-Myers SquibbSep 18, 201718
NCT03003962Non Small Cell Lung Carcinoma NSCLC · United States, Australia, China and more3Active, not recruitingAstraZenecaOct 27, 2022669

How it is read

Names in the registry

  • “Durvalumab”, 55 entries
  • “MEDI4736”, 20 entries
  • “durvalumab”, 7 entries
  • “MEDI4736 (Durvalumab)”, 3 entries
  • “MEDI4736 + tremelimumab”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.